ADVERTISEMENT
3D illustration of T cell attached to protein
“Smarter” CAR T Cells Target Tumors with Precision
Two studies in mice now show that researchers can control when and where CAR T cells are active, potentially overcoming previous hurdles for CAR T–based treatments.
“Smarter” CAR T Cells Target Tumors with Precision
“Smarter” CAR T Cells Target Tumors with Precision

Two studies in mice now show that researchers can control when and where CAR T cells are active, potentially overcoming previous hurdles for CAR T–based treatments.

Two studies in mice now show that researchers can control when and where CAR T cells are active, potentially overcoming previous hurdles for CAR T–based treatments.

CAR T cells
Artist's rendition of a yellow CAR T cell near a red cancer cell surrounded by red blood cells.
Ten Years On, CAR T Cell Recipient Is Still Cancer-Free
Jef Akst | Feb 3, 2022 | 2 min read
First, the genetically engineered cells became CD8+ killer T cells that wiped out his leukemia. Then they transformed into a stable population of CD4+ helper T cells that continue to circulate in his body.
knitted pink heart with a mended hole
CAR T Cells Mend Broken Mouse Hearts
Sophie Fessl, PhD | Jan 6, 2022 | 4 min read
Specialized immune cells generated in vivo reduce cardiac scar tissue in mice, a new study shows.
Neoantigen Prediction for Precision Immunotherapies
Neoantigen Prediction for Precision Immunotherapies 
The Scientist Creative Services Team | 1 min read
Learn about the tools and resources researchers use to define, discover, and deploy anti-tumor immunotherapies.
CAR Macrophages Tackle Challenges in Solid Cancer Treatment
Amanda Heidt | Mar 26, 2021 | 6 min read
Following on the success of CAR T cells used to treat cancers of the blood, researchers have launched a Phase 1 clinical trial of genetically modified macrophages to target solid tumors.
Bispecific Antibodies Treat Cancer in Mouse Models
Abby Olena, PhD | Mar 5, 2021 | 4 min read
A trio of papers shows that specialized antibodies can direct T cells to destroy cells that display portions of mutant cancer-related proteins, as well as T cells that have become cancerous themselves.
3D medical illustration of peripheral blood cells: a lymphocyte (left) and a monocyte (right) surrounded by red blood cells.
PBMCs: Mononucleated and Multipurposed
Deanna MacNeil, PhD | 4 min read
Researchers employ peripheral blood mononuclear cells (PBMCs) in clinical and academic applications related to the immune system and regenerative medicine.
CAR T cells, oncolytic virus, CD19, mouse model, solid cancer, liquid cancer, tumor, immune response, immunotherapy, T cell, treatment
Immunotherapy Combo Reduces Solid Tumors in Mice
Amanda Heidt | Sep 9, 2020 | 5 min read
When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.
Natural Killer Cell Therapies Catch Up to CAR T
Bianca Nogrady | Apr 1, 2020 | 8 min read
There’s a new cell-based cancer immunotherapy on the block.
Scalable and reproducible solutions in CAR T cell therapy workflows 
Advancing CAR T Cell Research and Development
Bio-Rad | 1 min read
How to develop the best CAR T cell product for preclinical use.
CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity
Amy Schleunes | Mar 24, 2020 | 5 min read
A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.
CRISPR-Edited Cells for Cancer Therapy Safe in Humans: Trial
Ashley Yeager | Feb 6, 2020 | 3 min read
In the first clinical study of its kind in the US, researchers used CRISPR to modify CAR T cells to make them more potent against cancer, but the clinical benefits are unknown.
A full blood sample vial lying on top of a piece of paper that reads “Acute lymphoblastic leukemia”.
Targeting Leukemia with T Cells That Avoid Self-Destruction
Deanna MacNeil, PhD | 3 min read
Researchers found that naturally-occurring CD7-negative T cells avoid self-destruction and are good effectors in CAR T therapy for T cell blood cancers.
car t chimeric antigen receptor t cell immunotherapy pyroptosis cell death perforin macrophage leukemia lymphoma
Side Effect of CAR T Therapy Caused by Pyroptosis: Mouse Study
Kerry Grens | Jan 20, 2020 | 2 min read
The immunotherapy induces a form of cell death in leukemia cells in mice that triggers cytokine release syndrome, a dangerous inflammatory reaction that occurs in some patients.
A Bright Scientific Future
Bob Grant | Jan 13, 2020 | 3 min read
We may not have personal jetpacks yet, but the past decade has been marked by life-science revolutions, and the coming years have even more biological breakthroughs in store.
A wrecking ball destroying a malignant cell as a 3D illustration
Armored CAR T Cells Break Through Immune Suppression in Solid Tumors
Jennifer Zieba, PhD | 3 min read
Researchers determined the safety and antitumor ability of genetically engineered CAR T cells that circumvent immune suppression in a prostate cancer phase I clinical trial.
cardiac fibrosis car t chimeric antigen receptor immunotherapy t cells fibroblasts cardiovascular disease
CAR T Immunotherapy May Find New Use in Treating Cardiac Fibrosis
Emma Yasinski | Sep 11, 2019 | 3 min read
Scientists show the approach can kill cells that cause hardening of heart tissue in mice.
cryopreservation facility
Immune Cell Bank Bets on Future CAR T Success
Nicoletta Lanese | Aug 16, 2019 | 6 min read
The company Cell Vault offers to hold consumers’ T cells for later use, but scientists suggest the service would benefit very few users.
Overcoming T Cell Therapy Barriers with Engineered Proteins
Overcoming T Cell Therapy Barriers with Engineered Proteins
The Scientist Creative Services Team | 1 min read
Shannon Oda will discuss how to develop novel engineered fusion proteins to improve T cell therapies against hematological and solid tumors.
car t cell chimeric antigen receptor b cell lymphoma cd19 kymriah yescarta
Clinical Trials Bite Off Chunk of CAR T Therapy Market
Kerry Grens | Jul 30, 2019 | 2 min read
About a quarter of lymphoma patients eligible for the cancer treatments are opting for experimental—and free—options instead.
ADVERTISEMENT